Premium
Enalaprilat, an intravenous angiotensin‐converting enzyme inhibitor, in hypertensive crises
Author(s) -
DiPette Donald J,
Ferraro James C,
Evans Robert R,
Martin Marcus
Publication year - 1985
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1985.159
Subject(s) - enalaprilat , blood pressure , medicine , bolus (digestion) , angiotensin converting enzyme , ace inhibitor , adverse effect , anesthesia , intravenous bolus , angiotensin ii
The effect of enalaprilat (MK‐422), a newly synthesized, intravenous, nonsulfhydryl, angiotensin‐converting enzyme inhibitor, was studied in seven patients with either severe or malignant hypertension. All subjects initially received a 1 mg bolus injection of enalaprilat followed in 30 minutes by 10 mg. Five subjects received an additional 40 mg. Mean (±SE) pretreatment blood pressure for the group was 226 ± 9/141 ± 7 mm Hg. Five minutes after the 1 mg enalaprilat dose, blood pressure decreased to 211 ± 10/131 ± 9 mm Hg and further fell to 201 ± 14/123 ± 11 mm Hg at 30 minutes. The maximal reduction in blood pressure to 169 ± 14/112 ± 10 mm Hg occurred 30 minutes after the 10 mg dose. No further blood pressure reduction was observed in those subjects who received the additional 40 mg dose. Within the entire group, five subjects exhibited sustained blood pressure reduction. No adverse side effects or symptomatic hypotension occurred in any subject. Clinical Pharmacology and Therapeutics (1985) 38, 199–204; doi: 10.1038/clpt.1985.159